IOL Chemicals and Pharmaceuticals Q4 FY26: Margin rebound led by pharma mix

IOL Chemicals and Pharmaceuticals Limited closed Q4 FY26 with a clear improvement in profitability, backed by stronger operating leverage and a better mix in the pharmaceuticals business. Revenue from operations for the quarter rose to ₹619.5 crore, up 17.4 percent year on year. EBITDA grew faster than revenue, increasing 39.8 percent year on year to ₹94.3 crore, taking EBITDA margin to 15.2 percent from 12.7 percent in Q4 FY25. Profit after tax (PAT) came in at ₹53.2 crore, up 68.2 percent year on year, with PAT margin improving to 8.6 percent.

For the full year FY26, the story was similar but more measured. Revenue from operations reached ₹2,319.1 crore, an 11.5 percent year on year increase. EBITDA rose 29.3 percent to ₹290.4 crore, lifting margin to 12.4 percent from 10.7 percent in FY25. PAT increased 36.4 percent to ₹137.7 crore, and the company ended the year with a stronger earnings base despite a higher cost structure in areas like employee expenses.

The quarterly results are also notable because Q4 FY26 looks like a reset quarter after a softer Q3 FY26 in profitability. EBITDA moved from ₹62.6 crore in Q3 FY26 to ₹94.3 crore in Q4 FY26, and PAT moved from ₹20.6 crore to ₹53.2 crore over the same period. The quarter therefore signals that the business can generate a higher earnings run rate when segment profitability aligns and operating execution stays tight.

Pharma powered the operating swing

The pharmaceuticals segment was the key driver of the improvement. In FY26, pharma revenue increased to ₹1,396.3 crore from ₹1,212.3 crore in FY25, while segment EBIT rose to ₹172.3 crore from ₹126.3 crore. The step up was even clearer at the quarterly level. Pharma revenue in Q4 FY26 came in at ₹374.5 crore versus ₹322.3 crore in Q4 FY25. Segment EBIT grew sharply to ₹62.2 crore from ₹40.9 crore.

This matters because IOL has been working toward reducing dependence on a single product cluster within APIs. The presentation highlights that within pharma, Ibuprofen contribution has moved down from 82 percent in FY21 to 63 percent in FY26, while other APIs have increased from 18 percent to 37 percent. That shift helps in two ways. It improves resilience when one molecule sees pricing pressure, and it expands the surface area for regulated market filings, since the company already has 14 DMFs with USFDA and 21 CEPs with EDQM.

The company’s capacity base supports this portfolio direction. It remains a large global producer of Ibuprofen with complete backward integration and annual capacity of 12,000 MT. At the same time, it has built a fully backward integrated and automated Paracetamol facility with annual capacity of 10,800 MT. This combination helps the company remain competitive in scale molecules while building a broader non Ibuprofen pipeline, where it has stated 20 products commercialized and 9 products in the pipeline.

Chemicals improved, but remains the second engine

The specialty chemicals segment also improved, though on a smaller base than pharma. For FY26, chemicals revenue net of intersegment rose to ₹922.8 crore from ₹866.9 crore in FY25. Segment EBIT increased to ₹30.2 crore from ₹15.4 crore. In Q4 FY26, chemicals revenue was ₹244.9 crore versus ₹205.5 crore in Q4 FY25, and EBIT increased to ₹12.8 crore from ₹6.5 crore.

The chemicals business is strategically important because it supports both merchant sales and internal supply of key inputs. The portfolio includes Ethyl Acetate with capacity of 1,20,000 MTPA, Acetic Anhydride with 32,000 MTPA, Iso Butyl Benzene at 12,000 MTPA, Mono Chloro Acetic Acid at 7,200 MTPA, Acetyl Chloride at 5,200 MTPA, and Triacetin at 6,000 MTPA. The presentation also notes REACH certification for Ethyl Acetate and Acetic Anhydride, which supports exports to the EU market.

In FY26, exports were 24 percent of revenue and domestic was 76 percent. This split indicates that the company is still largely driven by India demand, but it has a meaningful export business that can scale with regulatory approvals and market access.

Financial snapshot

The cost line in Q4 FY26 shows how the margin expanded. Cost of materials consumed was ₹401.7 crore, while inventory change provided a negative expense of ₹33.2 crore, supporting gross profitability for the quarter. Employee benefits expense rose to ₹70.3 crore from ₹52.4 crore, and other expenses increased to ₹84.3 crore from ₹66.7 crore. Even with these increases, EBITDA expanded sharply because revenue grew and operating contribution improved.

At the annual level, FY26 employee benefits expense increased to ₹248.3 crore from ₹216.6 crore, and other expenses rose to ₹314.6 crore from ₹268.6 crore. Depreciation also increased to ₹80.2 crore from ₹71.9 crore, reflecting a larger asset base. Despite these headwinds, operating margin improved meaningfully, suggesting that mix and scale gains offset the higher overhead burden.

Balance sheet discipline and cash conversion

The balance sheet shows a company still running with relatively low leverage. Total equity increased to ₹1,798.4 crore as of March 2026 from ₹1,687.4 crore in March 2025. Debt to equity ratio is stated at 0.08. Borrowings are present in current liabilities at ₹132.0 crore versus ₹117.0 crore in March 2025, while non current borrowings are nil.

Capital work in progress increased to ₹93.6 crore from ₹20.8 crore, pointing to ongoing projects even after a lower capex year. FY26 capex spent is shown at ₹164 crore versus ₹232 crore in FY25.

On cash flows, FY26 net cash from operating activities was ₹214.4 crore versus ₹178.7 crore in FY25. Net investing cash flow was negative ₹198.1 crore, and financing cash flow was negative ₹29.0 crore. Cash and cash equivalents ended the year at ₹65.3 crore compared to ₹78.0 crore a year earlier.

Working capital movement was slightly negative, with changes in working capital at minus ₹17.2 crore in FY26 compared to minus ₹20.7 crore in FY25. Trade receivables increased to ₹603.1 crore from ₹513.7 crore, and trade payables rose to ₹482.6 crore from ₹427.6 crore. Inventories were broadly stable at ₹371.1 crore versus ₹360.6 crore. The overall picture suggests the company is funding growth while keeping working capital swings manageable, though receivables growth is something investors typically track in fast growing quarters.

Strategy is centered on integration, diversification, and regulated markets

The presentation lays out a consistent operating philosophy: backward integration once scale is proven, followed by disciplined capacity expansion. This approach is especially relevant for molecules and intermediates where feedstock and quality control drive long term competitiveness. The specialty chemicals portfolio supports this structure by providing key inputs for APIs and a merchant product base.

The company has also invested heavily in compliance and market access. It has USFDA approved facilities, EU GMP certification, EDQM certificates of suitability, and multiple other certifications, including REACH. In May 2024, it received approval following ANVISA Brazil GMP inspection covering all 10 APIs manufacturing units. Regulatory depth matters because it reduces market concentration risk and increases optionality when global customers diversify supply chains.

The market context in the presentation supports this direction. Globally, the API market is shown at USD 245.59 billion in 2024, projected to reach USD 368.98 billion by 2033. India’s API market is shown at USD 17.77 billion in 2024, projected to reach USD 38.60 billion by 2033, with higher growth than global. The drivers listed include government incentives such as the ₹6,940 crore PLI scheme, strong regulatory compliance, supply chain diversification, and rising exports.

In specialty chemicals, India is positioned as a faster growing region. The presentation highlights India specialty chemicals market at USD 64.50 billion in 2024, projected to reach USD 92.60 billion by 2034. Region wise growth projections for FY25 to FY30 show India at 11 percent, higher than most other regions. For IOL, this backdrop aligns with its dual exposure to APIs and specialty chemicals.

Segment comparison: FY26 contribution and operating strength

Pharma’s role is evident not just in revenue share, but in profit share. The company also shows that pharma’s share of segmental revenue has risen to 60 percent in FY26, up from 57 percent in FY23. The trend suggests management execution is gradually moving the business toward higher value APIs while keeping the chemical chain relevant for both captive and merchant opportunities.

Way forward: land, filings, and resilience

Management has framed the next leg around three themes.

First is backend integration for margin stability and supply chain resilience. The company’s approach is to integrate key raw materials and intermediates after the product reaches meaningful scale. This is a conservative but practical method, since it avoids building capacity too early while still protecting long term economics.

Second is continued diversification beyond Ibuprofen. The presentation explicitly notes that non Ibuprofen share has increased from 18 percent to 37 percent over six years. Key products cited include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole. A broader basket can make quarterly results less dependent on one pricing cycle.

Third is export expansion, supported by 14 DMFs and 21 CEPs. With exports currently at 24 percent, there is room to scale overseas contribution, especially in regulated markets where compliance is a barrier to entry.

Alongside this, the company has acquired 101 acres of land near its existing facility along the Chandigarh Bathinda Highway. It is seeking clearances for industrial use, environmental compliance, and NHAI approvals. This land bank is a concrete signal of intent for future scale, even if near term capex was lower in FY26.

Investor takeaways

Q4 FY26 showed that IOL can expand margins meaningfully when the pharma segment delivers strong EBIT and when operating leverage plays out. The full year FY26 numbers confirm an earnings recovery, with EBITDA margin back to 12.4 percent and PAT growing 36.4 percent.

The bigger message is strategic clarity. The company is using backward integration as a cost and quality lever, while steadily increasing the share of non Ibuprofen APIs. It also continues to invest in regulated market access through filings and certifications. With low leverage, ongoing project work visible in capital work in progress, and a new land parcel for expansion, the platform looks geared for the next stage.

The near term investor focus is likely to remain on two questions: whether the improved Q4 margin profile can sustain through FY27, and how quickly exports and the non Ibuprofen portfolio can scale without stretching working capital. If execution stays consistent, FY26 may be remembered as the year IOL shifted from recovery to a more balanced growth model.